Refining treatment guidelines in Alzheimer's disease

Geriatrics

Volumn 60, Issue 6 SUPPL., 2005, Pages 14-20

  Doody, Rachelle S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; PLACEBO; RIVASTIGMINE; TACRINE; ANTIPARKINSON AGENT; INDAN DERIVATIVE; NOOTROPIC AGENT; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; CONFUSION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; LIVER TOXICITY; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; OUTCOMES RESEARCH; PRACTICE GUIDELINE; AGED; CLASSIFICATION; FEMALE; HOSPITALIZATION; MALE; REVIEW; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS; FEMALE; HUMANS; INDANS; MALE; MEMANTINE; NOOTROPIC AGENTS; PIPERIDINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20544448027     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56:1154-1166.
2. Reisberg B, Doody R, Stöffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341.
3. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-324.
4. Doody RS. Current treatments for Alzheimer's disease: cholinesterase inhibitors. J Clin Psychiatry. 2003;64 Suppl:911-917.
5. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001;57:613-620.
6. Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999;14:135-146.
7. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41-45.
8. Schmitt FA, Ashford W, Ernesto C, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11(Suppl 2):S51-S56.
9. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308-2314.
10. Data on file, Forest Laboratories, Inc.
11. Doody R, Wirth Y, Schmitt F, Möbius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2004;18:227-232.
12. Peskind ER, Potkin SG, Pomara N, et al. Memantine monotherapy is effective and safe for the treatment of mild to moderate Alzheimer's disease: a randomized, controlled trial. Eur J Neurol. 2004;11(Suppl 2):186. Abstract.
13. Sumaira R, Doody R, Lai E. Profoundly advanced Alzheimer's Disease patients: patient characteristics, functional status, disease progression and caregiver burden. Neurology. 2000;54(Suppl 3):A417 Abstract.